TY - JOUR
T1 - The water-perfusable tissue fraction of colorectal cancer metastases is increased by the selective PDGF-receptor inhibitor imatinib but not the IL-1 receptor antagonist anakinra, a study using serial dynamic 15O-water PET.
AU - Lubberink, Mark
AU - Golla, Sandeep S V
AU - Jonasson, My
AU - Rubin, Kristofer
AU - Glimelius, Bengt
AU - Sörensen, Jens
AU - Nygren, Peter
PY - 2015
Y1 - 2015
N2 - High interstitial fluid pressure (IFP) in colorectal cancer metastases may decrease the uptake and, thus, the effects of anti-tumor drugs. Imatinib, a selective inhibitor of PDGF receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increase drug uptake and/or decrease IFP in preclinical models of carcinoma. Drug-induced decrease in IFP in human metastases has not been objectively shown, but should be reflected by an increase in water-perfusable tissue fraction (PTF) or tumor blood flow (TBF) using [(15)O]water PET/CT and kinetic modelling. Hence, the aim of this study was to assess the effects of imatinib and anakinra on PTF and TBF in colorectal cancer metastases in patients.
AB - High interstitial fluid pressure (IFP) in colorectal cancer metastases may decrease the uptake and, thus, the effects of anti-tumor drugs. Imatinib, a selective inhibitor of PDGF receptors, and anakinra, an interleukin-1 receptor antagonist, respectively, increase drug uptake and/or decrease IFP in preclinical models of carcinoma. Drug-induced decrease in IFP in human metastases has not been objectively shown, but should be reflected by an increase in water-perfusable tissue fraction (PTF) or tumor blood flow (TBF) using [(15)O]water PET/CT and kinetic modelling. Hence, the aim of this study was to assess the effects of imatinib and anakinra on PTF and TBF in colorectal cancer metastases in patients.
U2 - 10.2967/jnumed.114.151894
DO - 10.2967/jnumed.114.151894
M3 - Article
C2 - 26069310
SN - 0161-5505
VL - 56
SP - 1144
EP - 1149
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 8
ER -
